Jeffrey Weber, MD, PhD, NYU Langone Health, Perlmutter Cancer Center
Advertisement
Articles by Jeffrey Weber, MD, PhD, NYU Langone Health, Perlmutter Cancer Center
Advertisement
Latest Updated Articles
Rapids Readouts: Phase 3 CheckMate 238 TrialPublished: October 30th 2020 | Updated:
Dr. Jeffrey Weber on CheckMate-064 Trial for Advanced MelanomaPublished: June 13th 2016 | Updated:
Dr. Jeffrey S. Weber on Why the Results of CheckMate-064 Were SurprisingPublished: August 21st 2016 | Updated:
Dr. Weber on Risk and Benefits With Immunotherapy Combos in MelanomaPublished: December 23rd 2016 | Updated:
Dr. Weber on CheckMate-238 Compared With Other Trials in MelanomaPublished: September 28th 2017 | Updated:
Dr. Weber on the Toxicity Profile of Nivolumab Versus Ipilimumab for MelanomaPublished: November 9th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5